NASDAQ:NRIX Nurix Therapeutics Q4 2024 Earnings Report $17.55 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$17.40 -0.16 (-0.88%) As of 06/18/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Nurix Therapeutics EPS ResultsActual EPS-$0.75Consensus EPS -$0.67Beat/MissMissed by -$0.08One Year Ago EPSN/ANurix Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANurix Therapeutics Announcement DetailsQuarterQ4 2024Date1/28/2025TimeAfter Market ClosesConference Call DateTuesday, January 28, 2025Conference Call Time4:00PM ETUpcoming EarningsNurix Therapeutics' Q2 2026 earnings is estimated for Thursday, July 9, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, July 8, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Nurix Therapeutics Earnings HeadlinesNurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Rating of "Moderate Buy" from AnalystsJune 20 at 2:31 AM | americanbankingnews.comZyVersa Therapeutics (NASDAQ:ZVSA) vs. Nurix Therapeutics (NASDAQ:NRIX) Head-To-Head AnalysisJune 17 at 4:49 AM | americanbankingnews.comA huge SpaceX error just led one stock to 3X move!SPCE surged roughly 300% in a single week after investors hunting SpaceX exposure piled into the wrong ticker. That window has closed - but the next opportunity may still be open. Trader Lance Ippolito has released a free SpaceX Investing Blackbook covering pre-IPO positioning plays, the space stock Goldman Sachs, BlackRock, and Morgan Stanley are loading up on, and the chip supplier Starlink satellites depend on.June 20 at 1:00 AM | InvestPub (Ad)Nurix Therapeutics (NRIX) Stock Looks Expensive Even With A $31 Analyst TargetJune 16, 2026 | finance.yahoo.comTruist is Bullish on Nurix Therapeutics, Inc. (NRIX)June 16, 2026 | finance.yahoo.comTruist is Bullish on Nurix Therapeutics, Inc. (NRIX)June 16, 2026 | insidermonkey.comSee More Nurix Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nurix Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nurix Therapeutics and other key companies, straight to your email. Email Address About Nurix TherapeuticsNurix Therapeutics (NASDAQ:NRIX) is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology. The company’s pipeline includes multiple programs in various stages of development. Among these are targeted protein degraders designed to eliminate key signaling proteins implicated in B-cell malignancies and inflammatory disorders. Nurix advances both proprietary and partnered assets, leveraging its Maestro™ platform to generate novel therapeutic candidates that reflect its expertise in medicinal chemistry, structural biology and protein degradation technologies. Founded in 2015 and headquartered in San Francisco, California, Nurix collaborates with leading pharmaceutical companies to accelerate discovery and development. These strategic alliances complement the company’s in-house capabilities, enabling the translation of early research into clinical candidates and enhancing its capacity to address diseases that have proved difficult to treat with conventional approaches. Under the leadership of Chief Executive Officer Christalynn Sayers and an experienced management team, Nurix Therapeutics continues to advance its proprietary pipeline through clinical trials and regulatory engagements. The company remains committed to pioneering new modalities that selectively dismantle disease drivers, with the goal of delivering transformative medicines to patients worldwide.View Nurix Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Satellogic Is Tiny But Its Revenue Growth Is Hard to IgnoreAehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?Why Kroger’s Pullback Could Be a Gift for Patient InvestorsCredo Technologies Accelerates AI—Its Stock Price Will FollowWhy Palantir’s Google Cloud Deal Could Change the DebateAmerican Eagle’s Q1 Beat Leaves Investors With a Bigger QuestionCarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Upcoming Earnings FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
